Inflammatory & Autoimmune Diseases

Actemra (tocilizumab)

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

Actemra is a first-in-class anti-IL-6 receptor (aIL-6R) therapy. IL-6 is believed to play a key role in activating the inflammatory pathway that contributes to the signs and symptoms of RA and other inflammatory autoimmune conditions. Actemra binds to IL-6 receptors, blocking the pro-inflammatory effect of IL-6 cytokines.

Actemra is approved for the treatment of rheumatoid arthritis (RA), pediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis (GCA), CAR-T cell-induced cytokine release syndrome (CRS), and certain hospitalized adult patients with coronavirus disease 2019 (COVID-19). 

Actemra is available in both subcutaneous (SC) and intravenous (IV) formulations.

In case of any adverse events or safety queries, please contact:

If you have a scientific query related to one of Roche's products, please contact:

M-PK-00001707

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsRoche careersPrivacy StatementLegal Statement

Please be aware that you are leaving this website.